CRD-38

On Tuesday, Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) announced positive study results demonstrating that subcutaneously administered cannabidiol - the active pharmaceutical ingredient in Cardiol's novel CRD-38 subcutaneous (SUBQ) formulation - slowed increases in body weight...